11^th Global Medical Microbiology Summit & Expo

Applied Microbiology in Clinical Research

Submit Abstract Register Now

Monitoring viral DNA or RNA loads has become the standard of care for several chronic viral infections.  Genotyping for the detection of drug resistance is the standard of care to guide antiretroviral therapy and complements load assessment. Following on from the success of molecular methods for the detection of several bacterial infections, genotypic detection of antibiotic resistance is appealing due to the avoidance of problems such as variable phenotypic resistance expression.  Unlike specific PCR testing where a particular organism is being sought, the use of broad-range PCR for the diagnosis of infectious diseases is more of a fishing expedition. Despite significant advantages of molecular diagnostics it cannot yet replace conventional methods for a range of infectious diseases since many common tests performed in the clinical microbiology laboratory are rapid and inexpensive.

The global clinical microbiology market is valued at $6,727.29 million in 2014 and is expected to grow at a CAGR of 13.03% between 2014 and 2019. Increasing disease burden of infectious diseases and increased funding for healthcare expenditure are the important growth drivers for this market during the forecast period.